Joerg Hoelzing, PhD

Come join us at #SCOPEsummit Europe in Barcelona for an insightful panel discussion on integrating Digital Health Technologies in Clinical Trials: A New Era for eCOA and ePRO with Jacqueline Bowman, LLB, MBA, Kai Langel, and Bernhard Glombitza. We will explore how emerging digital health technologies, particularly eCOA and ePRO, are reshaping patient data collection in clinical trials. Discover the evolution of digital endpoints, patient-centric strategies, and the incorporation of these technologies into clinical research frameworks. How are eCOA and ePRO solutions revolutionizing data collection in clinical trials? Have they enhanced the patient-centricity of trials? Explore the challenges in integrating these technologies into existing clinical trial structures and the strategies for overcoming them. What factors should be considered when selecting technology partners? Looking ahead, let's discuss the future of digital health technologies and their impact on clinical research. Join the conversation to gain valuable insights into the evolving landscape of digital health technologies in clinical trials at #SCOPEsummit. Micah Lieberman Rich Handy Melissa M. Dolen Erin Kadelski

15

TOM is a swiss #digitalhealth startup with expertise on #therapies from the #patient perspective. We have developed a new approach that links anonymous patient feedback directly with therapy data/RWD from 350,000 patients to provide much faster and more precise answers then ever before. If you are interested in how we do this, we would be happy to present some of the use cases that we are currently implementing with pharmaceutical companies. Just drop a message to our Co-Founders Redona Hafizi, PhD or Sven Beichler. Fast, safe and anonymous. How patient surveys work in TOM: https://lnkd.in/gzaiP2zd #patientfirst #patientcentricity #realworlddata #patientsvoice

10

🌟 Introducing our new #MedTech ecosystem map!   🗺️ Discover the vibrant #MedicalTechnology landscape in the Greater Zurich Area with our latest map. Featuring MedTech companies, medical products & devices companies, universities and research institutions, as well as public organizations and platforms, our map provides a comprehensive overview of the key players in the region.   🔬 Why do so many MedTech companies choose the #GreaterZurichArea? The region stands out for its unique exchange of knowledge and expertise between industry-leading companies and top research institutions. This creates a remarkable synergy that fosters #innovation and drives technological breakthroughs.   🌐 This environment also attracts significant capital and #talent. Proximity to a major financial center offers excellent funding opportunities, while renowned universities draw international students and future professionals, making Greater Zurich a global talent hub.   🔍 Explore the dynamic MedTech ecosystem of the Greater Zurich Area here: https://lnkd.in/dPfCUffP. To directly download the MedTech ecosystem map, click here: https://lnkd.in/d3gk-9qZ.

82

15 Kommentare

We won the Health-X Fellowship Prize at the 5th Health-X dataLOFT Innovation Forum last week in Berlin! As part of this recognition, VEIL.AI will collaborate with leading experts from the Health-X dataLOFT consortium. Furthermore, this will open doors to integrate the VEIL.AI Anonymization Engine (VAE) into the Health-X dataLOFT platform. Health-X dataLOFT is tasked with developing a platform suitable for the emerging European Health Data Space (EHDS) in German and Europe. The Health-X Fellowship supports the development and scaling of innovative health solutions - like VEIL.AI’s - that align with the goals of the EHDS and Gaia-X Association for Data and Cloud (AISBL) (Gaia-X Hub Germany). VEIL.AI is capable of providing robust anonymization solutions and tools for GDPR and EHDS-compliant verification of data anonymity, supporting various use cases from research applications to AI/ML model training. The integration of VAE into the Health-X DataLOFT platform will promote secondary data usage and marks a strategic advancement in managing and protecting health data in Europe. By enabling more efficient and secure use of anonymized data, VEIL.AI will drive research and innovation, ensuring that the Health-X platform remains at the forefront of data privacy and utility in alignment with EHDS. Our team members - Chief Product Officer Max Salmi and Senior Data Scientist/Engineer Susanne Hultsch, PhD had a really good time at the event. A big thanks to the organizers, moderators Tim Schurig and Arthur Kari (from Freie Universität Berlin), the jury and all participants who contributed to a very fruitful discussion! Congratulations to other winners elbtech GmbH Recovery Cat Preventicus GmbH Berlin Institute of Health @Charité - Universitätsmedizin Berlin Digital Entrepreneurship Hub #EHDS #GDPR #dataprivacy #dataanonymization #innovation #rnd #healthtech #healthdata #secondarydatausage #integration #federatedlearning

70

11 Kommentare

Transforming Swiss medicine: b-rayZ at the SP Health Colloquium in Bern🇨🇭 We are pleased to announce that b-rayZ's CEO, Cristina Rossi, will participate as a featured speaker at this year's SP Health Colloquium, scheduled for May 3rd at the Bundeshaus in Bern. This event is pivotal in discussing the integration of artificial intelligence within healthcare, with a focus on the legal, ethical, and practical dimensions. Cristina's presentation, titled "Breast Cancer Early Detection Through AI," will explore how digitalization is transforming Swiss medicine, demonstrating b-rayZ's leadership in applying AI for improved diagnostics. Her insights will underscore the growing necessity for digital tools in enhancing patient outcomes and streamlining medical processes in Switzerland. Discussions will revolve around the importance of creating transparent, safe, and well-regulated frameworks to foster the large-scale adoption of these technologies. Such frameworks are crucial for ensuring that advancements in AI are both effective and ethically implemented. b-rayZ is committed to leading by example, showing how thoughtful regulation and cutting-edge technology can coexist to revolutionize healthcare. We look forward to engaging with policymakers and industry leaders to further this cause. 🙌 #bern #ai #medicine #healthcare #swiss #artificialintelligence #medtech

24

🚀 We are delighted to share that Mika Health has been recognized by the Fraunhofer IIS as a leading example of AI-based digital health applications! 🌟 In oncology, the potential of AI-powered health apps is immense, transforming patient care and improving outcomes. Our innovative solutions in Mika are designed to support patients and healthcare providers, making a meaningful impact in the fight against cancer. Thank you, Fraunhofer IIS, for this recognition. We are proud to be at the forefront of digital health innovation! 💙🤖 ➡ Read more in the recently published article by Healthcare Digital on the the potential of purposeful AI in healthcare here: https://lnkd.in/dEVR6M5C #DigitalHealth #AI #Oncology #Innovation #Healthcare

20

2 Kommentare

Chief AI Officers in Healthcare: CAIO's emerging now with a big future ahead Chief Artificial Intelligence Officers (CAIOs) are a new but increasingly important role in healthcare. As AI technology becomes more integrated into medical practices, healthcare organisations are looking for leaders to develop strategy and implementation, effectively communicate the benefits and risks of AI to all stakeholders and oversee the development and use of AI to ensure it is fair, unbiased, and adheres to patient privacy regulation. The future of Chief AI Officers (CAIOs) in healthcare appears bright, with their roles likely to evolve and expand as AI becomes even more ingrained in the industry. Here are some potential areas of growth: > Focus on Interoperability and Integration: As the number of AI tools used in healthcare grows, CAIOs will play a crucial role in ensuring they work seamlessly together. This will involve creating standards for data exchange and promoting the development of interoperable AI platforms. > Proactive Exploration and Innovation: Beyond foundational models, CAIOs will likely move towards exploring cutting-edge AI applications in areas like personalised medicine, drug development, and even robotic surgery. They'll be responsible for identifying promising new technologies and guiding their implementation. > Addressing Equity and Accessibility: A crucial aspect will be ensuring that AI advancements benefit all patients equally. CAIOs will need to address issues of bias in algorithms and work towards developing AI solutions that are accessible to everyone, regardless of location or socioeconomic background. > Building Public Trust and Transparency: As AI plays a more prominent role in healthcare decisions, maintaining public trust will be essential. CAIOs will be responsible for communicating the benefits and limitations of AI to the public and ensuring transparency in how AI is used. Mergers, Acquisitions, Growth and Strategy for Healthcare Technology companies in EMEA > Healthcare Technology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions. Visit https://lnkd.in/eesJTA9s > HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors. Email lloyd@nelsonadvisors.co.uk  > HealthTech M&A Newsletter from Nelson Advisors - HealthTech, Health IT, Digital Health Insights and Analysis. Subscribe Today! https://lnkd.in/e5hTp_xb > HealthTech Corporate Development and M&A - Buy Side, Sell Side, Growth & Strategy services for companies in Europe, Middle East and Africa. Visit www.nelsonadvisors.co.uk  https://lnkd.in/ejVhzu44

1

❓❓Did you like the dynamic format of the Geneva Digital Health Day (#GDHD), with short pitches, lightning talks and insightful keynotes that created an engaging day for all involved? Take it a step further with IMPLEMENTATION REPORTS - a checklist and PubMed-indexed reporting format specifically designed to document and publish digital health implementations. Published in JMIR Publications, this format ensures that your implementation efforts are systematically reported and widely recognised. 🔍 Example in action: The Concerto app, designed to empower hospitalised patients at a Swiss university hospital, was presented at the #GDHD. The project's development, design and implementation were thoroughly documented using the Implementation Report, demonstrating its effectiveness in capturing the nuances of digital health implementation. Read the full publication here: 🖇 https://lnkd.in/dpxHCd_X 🔴 Call to Action: We invite our network and the wider digital health community to adopt the IMPLEMENTATION REPORT. By doing so, we can improve the quality, transparency and impact of implementation research in digital health. Check-list & Implementation Reports: https://lnkd.in/efg5jQ5q 💡Let's learn and document our successes and failures to scale up digital health together D-tree, Pranav Savanur, VillageReach, Edwin Mulwa, Jessica Mayenda, Philippe Guinot, Laurie Werner, Lola Aderemi, Janet Michel, Daniel Otzoy Garcia, Smisha Agarwal, Patty Mechael, Derrick Muneene, Gurmit Sandhu, Hannu Vuola, Dr. Rajendra Pratap Gupta, PhD Lisette Schutte, PhD, Dr Osama Elhassan, Nada MALOU, Laurent Bonnardot, Osman Ratib, Enya Séguin, Mathieu Morand, Megha Kosaraju Kumar, Tiffany Corbet, Kallol Mukherji, Talia Salzmann, Martyn Clark, Pixels Trade SA, Skander Douki, Lucas Poingt. Centre de l'innovation des HUG #DigitalHealth #Innovation #Implementation #GenevaDigitalHealthDay #ConcertoApp #JMIR

49

2 Kommentare

Artificial Intelligence (#ai) is transforming the #patientcare journey by enabling targeted #interventions at every stage and touchpoint, ensuring a more #personalized and efficient #healthcare experience. From the initial diagnosis to treatment and follow-up, AI's capabilities in #dataanalysis, #patternrecognition, and #predictiveanalytics allow healthcare providers to tailor their approaches to the unique needs of each patient. AI-driven #diagnostictools can quickly analyze complex medical images or genetic information to identify diseases at their earliest stages, often before patients exhibit any symptoms. AI #algorithms can sift through vast amounts of #medicalliterature and #patientdata to recommend the most effective treatment plans, considering factors like potential side effects and individual health conditions. This precision not only improves patient outcomes but also enhances the overall efficiency of healthcare delivery by prioritizing resources where they are most needed. Benefits of #ai extends beyond #clinicalinterventions, touching upon various aspects of the #patientexperience. Through personalized #healthapps and #wearabledevices, AI provides continuous monitoring and real-time feedback to patients, empowering them to manage their health proactively. These tools can remind patients to take their medication, suggest lifestyle adjustments, and even alert healthcare providers to potential health issues before they become serious. In post-treatment care, AI can analyze patient feedback and health data to predict the risk of readmission, enabling timely interventions to prevent complications. By seamlessly integrating into every touchpoint of the care journey, AI not only optimizes healthcare processes but also fosters a deeper connection between patients and their care providers, making healthcare more #responsive, #accessible, and centered around the needs of the patient. At, AI Nexus Healthcare, we offer innovative #aidriven solutions that add value at each #patienttouchpoint across the clinical spectrum, from diagnosis, early intervention to remote monitoring. For more information on our ground-breaking technology, visit our website: https://buff.ly/3JrAmkO #AINexus #DigitalHealthForAll #healthcareforall #digitalhealth #healthequity #healthtechnology #remotecare #virtualcare #remotemonitoring #PatientEngagement #HealthTech #DigitalHealthcare

13

The opportunities of #healthcareAI in early #LungCancer detection discussed in Madrid, Spain with global luminaries at the 𝗔𝗹𝗹𝗶𝗮𝗻𝗰𝗲 𝗳𝗼𝗿 𝗚𝗹𝗼𝗯𝗮𝗹 𝗜𝗺𝗽𝗹𝗲𝗺𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝗟𝘂𝗻𝗴 𝗮𝗻𝗱 𝗖𝗮𝗿𝗱𝗶𝗮𝗰 𝗘𝗮𝗿𝗹𝘆 𝗗𝗶𝘀𝗲𝗮𝘀𝗲 𝗗𝗲𝘁𝗲𝗰𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 aka AGILE.     Thank you International Early Lung Cancer Action Program (I-ELCAP) and iDNA - The Institute for DiagNostic Accuracy for organizing a thought-provoking forum. The conference enabled collaboration, engagement and knowledge development on meeting the challenges of early disease identification.     Each year, lung cancer claims more lives than breast, colon, prostate and ovarian cancer combined. Questing for #earlydetection means that treatment options are more effective and survival rates increase.     #healthtech #medicaldevices #medicalimaging #artificialintelligence #oncology #earlylungcancerdetection Bhargava Reddy Sagar Sen Preetham Putha Ranjana Devi Georgina Wright Ketaki Kakade Nikunj Mohota Aman Garg Samir Shah, MD, MMM FACR Surabhi Srivastava Rakhee Krishnan

88

2 Kommentare

Days 2 of the 40th annual conference of the DGPharMed is a wrap! With quite a range of topics, from digital health applications (#DiGA) to #AI in drug development, #HTA and access to the European market as well as patient centricity, developments from the point of view of ethics committees and more, the day was packed with exciting presentations and discussions. Here are my thoughts from day 2: 1️⃣ Jonas Albert gave a fantastic presentation about the pathway to approval for digital health applications, with lots of insights. His overview over the process, requirements (incl. randomized controlled trials that go beyond adherence and need to show a health benefit) and targeted devices made the topic very accessible, topped by a very energetic delivery of the information! 2️⃣ Thomas Kaiser gave a lovely presentation on how the unified EU health technology assessment (HTA) is going to be implemented from 2025 onwards. This included pointing out that the joint assessment does not include recommendations for EU member states who retain their sovereignty. Overall, it does not seem to significantly centralize the process. 3️⃣ Karin Arndt delivered a very powerful presentation on the patient perspective within clinical trials, highlighting her own story as a sarcoma patient. She turned this experience into an opportunity to help educate patients about clinical trials through PEAK, and continues advocating for how much patients, especially those terminally ill, often want to give their data to research. 4️⃣ Listening to Daniela Schemmer provide insights into the life as a clinical study coordinator and the logistical as well as emotional burden they face was eye opening to me. Hearing her speak about 50% of study coordinators retiring over the next 10 years with no replacement in sight was a scary thought. And a high note of absurdity: Trying to discuss a 38-page ICF with patients that just got a cancer diagnosis 🤷 5️⃣ At the end of the day we got back to discussing issues with site contracts. Unified contract requirements were already a discussion point on day one - with reference to the German constitution forbidding mandated contracts. Potential opportunities to streamline contracting with standard contractual clauses were discussed nevertheless, and incentives for using them could be a way to circumvent this restriction and help expedite contract timelines (from a reported median of 150 days...). Bonus point: ChatGPT suggesting post conference activities, including who can spit pills the farthest 😅 I love every opportunity to exchange with the #healthcare industry, as it is always bound to bring new points of view and enrich my perspective. #clinicalresearch #ichgcp

42

1 Kommentar

🚀 𝐈𝐧𝐭𝐫𝐨𝐝𝐮𝐜𝐢𝐧𝐠 𝐨𝐮𝐫 𝐥𝐚𝐭𝐞𝐬𝐭 𝐰𝐡𝐢𝐭𝐞 𝐩𝐚𝐩𝐞𝐫: "𝐓𝐡𝐞 𝐆𝐞𝐫𝐦𝐚𝐧 𝐃𝐢𝐆𝐀 𝐈𝐝𝐞𝐚"! 🚀 Discover how the 𝐃𝐢𝐆𝐀 (𝐃𝐢𝐠𝐢𝐭𝐚𝐥 𝐇𝐞𝐚𝐥𝐭𝐡 𝐀𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬) concept, which originated in Germany, is revolutionizing health care by making validated health technologies accessible and reimbursable for patients. From its success in Germany, DiGA has rapidly gained traction across Europe and is now being noticed in the US. 𝐋𝐞𝐚𝐫𝐧 𝐚𝐛𝐨𝐮𝐭: • The fast track approval and reimbursement scheme • Insights from Dr Dr Cordula Stover presentation at the 12th Annual Outsourcing in Clinical Trials conference • The role of Contract Research Organizations (CROs) in navigating regulatory complexities 📥 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐭𝐡𝐞 𝐰𝐡𝐢𝐭𝐞 𝐩𝐚𝐩𝐞𝐫 𝐧𝐨𝐰 𝐚𝐧𝐝 𝐞𝐱𝐩𝐥𝐨𝐫𝐞 𝐡𝐨𝐰 𝐃𝐢𝐆𝐀 𝐢𝐬 𝐬𝐡𝐚𝐩𝐢𝐧𝐠 𝐭𝐡𝐞 𝐟𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐡𝐞𝐚𝐥𝐭𝐡 𝐜𝐚𝐫𝐞. 👉 https://lnkd.in/gfpzV7-4 Need more details? Head to our latest blog to get a preview of what you'll learn in the white paper 👉 https://lnkd.in/gempKz8j #RQMplus #DigitalHealth #HealthCareInnovation #DiGA #MedicalDevices #eHealth #mHealth

16

1 Kommentar

𝐏𝐚𝐫𝐭𝐢𝐜𝐢𝐩𝐚𝐭𝐞 𝐢𝐧 𝐚𝐧 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐯𝐞 𝐦𝐢𝐠𝐫𝐚𝐢𝐧𝐞 𝐭𝐡𝐞𝐫𝐚𝐩𝐲 𝐬𝐭𝐮𝐝𝐲 𝐚𝐭 𝐀𝐊𝐇 𝐕𝐢𝐞𝐧𝐧𝐚 We are thrilled to announce our upcoming #clinicaltrial under the expert guidance of Prof. Christian Wöber, 𝗛𝗲𝗮𝗱 𝗼𝗳 𝘁𝗵𝗲 𝗛𝗲𝗮𝗱𝗮𝗰𝗵𝗲 𝗖𝗹𝗶𝗻𝗶𝗰 at Universitätsklinikum AKH Wien. This initiative is aimed at pioneering new pathways in non-invasive brain stimulation for preventing 𝗺𝗶𝗴𝗿𝗮𝗶𝗻𝗲 attacks, a literal pain point affecting one million people across Austria. Prof. Wöber's dedication to helping migraine patients has also motivated him to write his recent book, which assists patients in identifying their profiles for the right treatment. Learn more here: https://lnkd.in/d3MxinJP 𝗪𝗲 𝗡𝗲𝗲𝗱 𝗬𝗼𝘂𝗿 𝗛𝗲𝗹𝗽! Are you or someone you know 𝘀𝘁𝗿𝘂𝗴𝗴𝗹𝗶𝗻𝗴 𝘄𝗶𝘁𝗵 𝗳𝗿𝗲𝗾𝘂𝗲𝗻𝘁 𝗺𝗶𝗴𝗿𝗮𝗶𝗻𝗲𝘀? If you experience more than 4 migraine attacks a month, you might be eligible to participate in our ongoing study. This is a unique opportunity to access innovative treatments and contribute to research that could change the lives of migraine sufferers worldwide. 𝗛𝗼𝘄 𝘁𝗼 𝗣𝗮𝗿𝘁𝗶𝗰𝗶𝗽𝗮𝘁𝗲: 𝗘𝗹𝗶𝗴𝗶𝗯𝗶𝗹𝗶𝘁𝘆: Individuals experiencing more than 𝟰 𝗺𝗶𝗴𝗿𝗮𝗶𝗻𝗲 𝗮𝘁𝘁𝗮𝗰𝗸𝘀 𝗽𝗲𝗿 𝗺𝗼𝗻𝘁𝗵 and able to travel to the AKH in 𝗩𝗶𝗲𝗻𝗻𝗮. 𝗕𝗲𝗻𝗲𝗳𝗶𝘁𝘀: Access to cutting-edge treatments and the chance to contribute to groundbreaking research. 𝗛𝗼𝘄 𝘁𝗼 𝗔𝗽𝗽𝗹𝘆: Express your interest and provide your preferred start date here: https://lnkd.in/d2hZat5A. Join us in advancing migraine research and developing more effective treatments. Your participation in the Brightmind study could help bring relief to millions. #MigraineResearch #ClinicalTrials #AKHVienna #Migraine

30

1 Kommentar

‼️ The problem with CIED infections is bigger than you think! At this year’s EHRA Congress in Berlin, consultant cardiologist Dr. Benito Baldauf presented new data from Germany: 27 million insurance beneficiaries were screened between January and December 2015. Among this population, there were 60,296 patients who underwent CIED procedures.  The 𝗿𝗮𝘁𝗲 𝗼𝗳 𝗖𝗜𝗘𝗗 𝗶𝗻𝗳𝗲𝗰𝘁𝗶𝗼𝗻𝘀 amounted to 𝟮.𝟳𝟱 % within 3 months following the index procedure. (1) ⚠️ This means that the 𝗽𝗿𝗲𝘃𝗮𝗹𝗲𝗻𝗰𝗲 𝗼𝗳 𝗖𝗜𝗘𝗗-𝗿𝗲𝗹𝗮𝘁𝗲𝗱 𝗶𝗻𝗳𝗲𝗰𝘁𝗶𝗼𝗻𝘀 𝗶𝘀 𝗮𝘁 𝗹𝗲𝗮𝘀𝘁 𝘁𝘄𝗼 𝘁𝗶𝗺𝗲𝘀 𝗯𝗶𝗴𝗴𝗲𝗿 than previously reported. Patients cannot afford taking risks. We must find effective solutions to prevent infections in rhythm surgery. Might 𝗧𝗮𝘂𝗿𝗼𝗣𝗮𝗰𝗲™ be the "silver bullet” (2), as Prof. Charles J. Love suggests?  💡 A 2023 study demonstrated that the adjunctive use of TauroPace™ can 𝗿𝗲𝗱𝘂𝗰𝗲 𝘁𝗵𝗲 𝗮𝗰𝘂𝘁𝗲 𝗖𝗜𝗘𝗗 𝗶𝗻𝗳𝗲𝗰𝘁𝗶𝗼𝗻 𝗿𝗮𝘁𝗲 𝘁𝗼 𝟬.𝟬𝟬 %. (3)    1) Baldauf. EHRA Congress 2024. ePoster Session 2, 8 April 2024, 12:30 pm.   2) Love. EP Europace 2023. DOI: 10.1093/europace/euad332  3) Borov et al. EP Europace 2023. DOI: 10.1093/europace/euad306 

37

1 Kommentar

Chantal Britt - thank you so much for your concise summary of the #patientinvolvement debate. You summarize a complex situation involving many stakeholders (and excluding some….) in a few sentences. And it’s perfectly fitting to the engaged and constructive discussions at the EUPATI Switzerland/ Schweiz / Suisse / Svizzera (EUPATI CH) General Assembly 2024. Together we are strong 💗 To know we have friends and allies in our common cause is of utmost importance 🙏🏼 #health #GoodHealth is a holistic concept of body&soul. So should #ResearchAndDevelopment of #healthcaresolutions be a holistic process ❣️

24

1 Kommentar

💥 Attention #DigitalHealth #Startups in Europe: Co-create & pilot a digital solution to capacitate patients who suffer #chronicpain The challenger: The Regional #HealthService of #Murcia (Servicio Murciano de Salud-SMS) provides healthcare to 1.47 million inhabitants (about 3.09% of the whole Spanish population). It integrates 11 hospitals, with 3,651 beds and more than 400 primary care centers. Through the HealthChain project, co-funded by the European Commission, SMS aims to address the PASPADOC challenge. Challenge main objectives: • A more efficient management of chronic pain from Healthcare Organization point of view • Improve accessibility and follow-up of patients with chronic pain • Promote self-empowerment among patients with chronic pain Solution proposed by the Leading SME: PALDOC: Chronic Pain Liquid Care Platform 🤝 What's in it for you? ✔ Access funding up to €50.000 ✔ Jointly co-create and pilot an innovative solution with a leading SME for a challenge identified by a healthcare organisation ✔ Get expert support on business modelling and market insights, and access to networks and resources ✔ Obtain the opportunity to work in an international partnership ✔ Network with other European SMEs and explore opportunities for forthcoming projects Pilot scope: ✔ The pilot will be developed in a total period of 12 months, including design, validation, testing and measuring of the impact of the co-created solution. ✔ It will include at least 30 patients, who will test the solution for 6 months. 💥 Adoption plans If the pilot is successful, SMS intends to adopt the solution, by a shared ownership of the solution co-created and procure its maintenance. 🕒 Don't miss out! 🔗 Apply on R2GConnect.com: https://lnkd.in/dhV_rzNg Ticbiomed #digitalhealth #globalhealth #healthcare #innovationmanagement #partnerships #codevelopment #pilot 

8

RWE | 🔍 What to Expect from RWE in the Future? Innovations in Study Design Real-World Evidence (RWE) has a profound impact on healthcare decisions, from treatment guidelines to policy reforms. Now, as we look to the future, it’s clear that RWE will continue to play an ever-expanding role in shaping the healthcare landscape. Traditional clinical trials have limitations, such as high costs and lengthy timelines. RWE will continue to innovate study designs, making research more efficient and accessible: 📊 PRAGMATIC TRIALS These trials, embedded within routine clinical care, will leverage RWE to compare treatment effectiveness. They offer the advantage of real-world relevance and cost-effectiveness. 🧠 MASTER PROTOCOLS These adaptive trial designs allow multiple treatments to be evaluated within a single trial. RWE will inform the selection of treatments and the adaptation of trial parameters. 🔬 SYNTHETIC CONTROL ARMS RWE can create synthetic control arms for clinical trials, reducing the need for placebo groups and allowing trials to be conducted with fewer patients. Let's embrace RWE to drive meaningful change in healthcare. Explore our ebook for a deeper dive into Real-World Evidence and the impact it has in Healthcare decision making. 🚀 https://lnkd.in/gsRg6YrS #RealWorldEvidence #RWE #Data #study #PatientCentricity

7